Kornimate/medical-research-clean huggingface dataset:
effect of ems and strengthening exercises on pain, fatigue and physical performance in motocross athletes

Conditions: Sports Injury

Summary: motocross, a popular sport, involves riding motorized vehicles on rugged tracks with obstacles. it's physically demanding, with high speeds and a risk of accidents. grip strength is crucial, especially in the arms and forearms, which are prone to injury. physiotherapy often employs strength exercises, including electromyostimulation. however, there's little research on their effectiveness for motocross athletes. this study aims to compare electromyostimulation combined with strength training versus strength training alone in relieving pain, fatigue, and improving strength in motocross athletes.

motocross is a popular sport in which participants ride a two-wheeled, motorized vehicle around a 2 km rugged track with natural or man-made obstacles. participants race at high speeds and it is considered a strenuous sport with a high accident rate. motocross racers grip the handlebars of their bikes with both hands throughout the race, which lasts between 18 and 26 minutes. therefore, it is a sports branch where control is concentrated on the arms and upper extremities. it has been reported that the most frequently injured and painful area is the forearm. therefore, good and strong upper extremity and forearm control is important for the prevention of injuries or subsequent recovery processes. it is known that strengthening exercise programs are used in physiotherapy practices to improve strength and stabilization parameters. the use of electromyostimulation applications for strengthening in different populations is also becoming widespread. there are no studies demonstrating the effectiveness of strengthening and electromyostimulation applications on pain, fatigue and strength parameters in motocross athletes. the aim of this study is to compare the effectiveness of electromyostimulation application applied simultaneously with a strengthening exercise program on pain, fatigue and strength, with strengthening exercises performed with sham application (electric current turned off).

Eligibility criteria:
inclusion criteria: * having at least 5 years of professional motocross training experience * being between 18 and 30 years old * volunteering to participate in the study exclusion criteria: * to be absent from the 6-week ems and strengthening program for more than 2 consecutive sessions * having suffered any injury that prevents you from training in the last 6 months * being receiving a physiotherapy program other than the protocol to be used in the study

Keywords: sports electromyostimulation exercise pain fatigue strength
allogeneic stem cell transplantation following chemotherapy in patients with hemoglobinopathies

Conditions: Hemoglobinopathies; Sickle Cell Disease; Thalassemia

Summary: the purpose of this study is to determine if treatment with reduced-dose busulfex, fludarabine and alemtuzumab (campath) followed by sten cell infusion will allow for donor stem cells to grow in patients with hemoglobinopathies bone marrow and restore circulating blood counts. in addition the incidence and severity of side effects and of graft vs. host disease (gvhd) will be monitored.

* in order to undergo transplant procedure, patients will be admitted to the hospital for approximately 10-14 days. * to prepare patient's bone marrow to accept donor stem cells, they will receive fludarabine and busulfex. fludarabine will be given intravenously once daily for 4 days. busulfex will be given once daily for the same 4 days. * one day before patients receive busulfex and fludarabine, they will also be given alemtuzumab intravenously once daily for 5 days. * three days after the end of chemotherapy, patients will receive the infusion of donor stem cells. * if patients have thalassemia, they will receive subcutaneous injections of filgrastim starting on day one after the donor stem cell transfusion and will continue receiving filgrastim every day until it appears that the donor stem cells have been accepted. if the patient has sickle cell disease, filgrastim will not be given, * additional drugs will be given to help prevent infection (i.e. antibiotics). * after stem cell infusion patients will be examined and have blood tests weekly for 1 month. bone marrow biopsies, and blood work will also be performed 1 month, 3 months, 6 months and 1 year after stem cell infusion. * patients will be on the study for about 12 months. after study is completed progress will be monitored on an annual basis.

Eligibility criteria:
inclusion criteria: * patients with sickle cell disease should have one or more of the following: acute chest syndrome requiring hospitalization; nonhemorrhagic stroke or central nervous system event lasting longer than 24 hours; recurrent caso-occlusive pain or recurrent priapism; sickle neuropathy; bilateral proliferative retinopathy and major visual impairment of at least one eye; osteonecrosis of multiple joints; transfusion dependence; vaso-occlusive. * patients with thalassemia should have one or more of the following: transfusion dependence; iron overload; presence of 2 or more alloantibodies against red cell antigens. exclusion criteria: * pregnancy * acute hepatitis * cardiac ejection fraction \< 30% * severe renal impairment * severe residual functional neurologic impairment * evidence of hiv infection

Keywords: hemoglobinopathies sickle cell anemia sickle cell-hemoglobin c disease sickle cell-b-thalassemia transfusion-dependant thalassemia allogeneic transplant nonmyeloablative transplant stem cell transfusion graft vs. host disease
identification of genes that predict local recurrence in samples from patients with breast cancer treated on nsabp-b-28

Conditions: Breast Cancer

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict whether cancer will come back after treatment. purpose: this research trial is studying genes that may predict local recurrence in samples from patients with breast cancer. treated on nsabp-b-28

objectives: * to evaluate the association between the 21-gene recurrence score and risk of local-regional recurrence (lrr) in node-positive, estrogen receptor- (er) positive (+) patients treated with cyclophosphamide and doxorubicin hydrochloride (ac) with or without paclitaxel in the nsabp-b-28 trial. * to evaluate the potential for combining the 21-gene recurrence score (rs) with traditional clinico-pathologic factors in order to derive an improved algorithm for prediction of lrr risk and in order to identify subgroups of er-positive patients with 1-3 or 4 or more positive nodes who do/do not need post mastectomy chest wall radiotherapy (xrt) or regional nodal xrt (irrespective of surgical procedure). * to evaluate whether the 21-gene rs predicts benefit from adding paclitaxel to ac chemotherapy in reducing risk of lrr, and improving disease-free survival (dfs) and overall survival (os) in node-positive, er-positive patients from nsabp-b-28. outline: rna extracted from paraffin-embedded tissue samples are analyzed for gene expression profile by ribogreen assay and rt-pcr. results are then compared and analyzed with each patient clinical-pathologic factors, including tumor size, patient age, number of positive nodes (1-3, 4+), tumor grade, and surgery type (mastectomy or lumpectomy).

Eligibility criteria:
disease characteristics: * diagnosed with breast cancer and enrolled on nsabp-b-28. * estrogen-receptor positive (er+) * node-positive disease * primary tumor tissue samples available * treated with cyclophosphamide and doxorubicin hydrochloride and tamoxifen with or without paclitaxel patient characteristics: * menopausal status not specified prior concurrent therapy: * see disease characteristics

Keywords: estrogen receptor-positive breast cancer stage ii breast cancer stage iiia breast cancer
combined use of contact aspiration and the stent retriever technique versus stent retriever alone for recanalisation in acute cerebral infarction

Conditions: Acute Ischemic Stroke

Summary: mechanical thrombectomy (mt) with a stent retriever (sr) device is now the standard intervention in ischemic stroke with large vessel occlusion. favorable outcome is strongly associated with the successful reperfusion status. new device of mt such as contact aspiration seems promising to increase reperfusion status and clinical outcome. the main hypothesis is to show the superiority of combining the use of contact aspiration with a stent retriever compared to a stent retriever alone in treatment of acute stroke due to proximal arterial occlusion. the primary endpoint is the rate of perfect reperfusion score at the end of the endovascular procedure.


Eligibility criteria:
inclusion criteria: * age 18 and older (i.e., candidates must have had their 18th birthday) * groin puncture carried out within 8 hours of first symptoms * neuroimaging demonstrates large vessel proximal occlusion (distal ica through mca bifurcation, m1 or m2) * consenting requirements met according to french laws. * with or without intravenous thrombolysis exclusion criteria: * absence of large vessel occlusion on non-invasive imaging * known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory * suspected pregnancy; if, a woman is of childbearing potential, a urine or serum beta human chorionic gonadotropin (betahcg) test is positive. * severe contrast medium allergy or absolute contraindication to iodinated agents. * patient has severe or fatal comorbidities that will likely prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient. * acute ischemic stroke involving posterior circulation (vertebrobasilar occlusion) * angiographic evidence of carotid dissection or tandem cervical occlusion or stenosis requiring treatment. * patients benefiting from a legal protection * non-membership of a national insurance scheme * opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person
comparison of radiological, clinical, functional outcomes between anatomically aligned total knee arthroplasty and conventional total knee arthroplasty

Conditions: Knee Arthropathy; Anatomically Aligned Total Knee Arthroplasty

Summary: total knee arthroplasty(tka) is a successful orthopedic surgery with excellent clinical outcome and survival. however, there are concerns about patient satisfaction in previous reports, and dissatisfaction rate of 15-30% is reported in clinical outcomes(proms) of some studies. therefore, for improving the patient's outcome and satisfaction after total knee arthroplasty, it is necessary to change the design of the conventional total knee arthroplsaty implant. the knee is a joint structure with several dynamic functions, and not only the skeletal structure but also the soft tissue balance plays an important role in the function of the knee joint. new implants are being developed to overcome the limitations of conventional tka implant, including the journey ii bi-cruciate substituting total knee system (jii-bcs; smith \& nephew). jii-bcs implant has normal articular geometry, more anatomical femoral shape, lateral tibial convex geometry, and asymmetrical tibial plateau, anterior and posterior cams, which has been shown in experimental studies to produce nearly normal knee movement by reproducing the actual normal anatomical alignment in vivo. the clinical results of the kinematic effects of this anatomcally aligned change are insufficient, and there is also a lack of comparative studies with conventional total knee arthroplasty implant. the purpose of this study is to compare outcomes between anatomically aligned tka(jii-bcs) and conventional tka(legion total knee system, smith \& nephew). this study is a randomized controlled study in patients undergoing same-day bilateral total knee arthroplasty. a patient undergoing same-day bilateral total knee arthroplasty will use a random number to determine the instruments(jii-bcs or legion), and both knee joints will be operated with the same instruments. radiologic parameter, patients preference and clinical results was investigated in patients who received tka during minimum 2 year follow up.


Eligibility criteria:
inclusion criteria: * patients for bilateral total knee arthroplasty * having medicare insurance exclusion criteria: * rheumatoid arthritis * other inflammatory arthritis * crystal-induced arthritis * septic arthritis * neuropsychiatric patients * previous knee operation history * neuropsychiatric patients * patients with preoperative severe limitation of motion (flexion contracture ≥ 20, range of motion ≤ 90) * patients with preoperative severe defomity of knee alignment (varus or valgus angle ≥ 15) * severe obese patients (bmi ≥ 40)
induction study #2 of oral ozanimod as induction therapy for moderately to severely active crohn's disease

Conditions: Crohn Disease

Summary: this is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active crohn's disease.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit: www.bmsstudyconnect.com inclusion criteria: * crohn's disease for ≥ 3 months on endoscopy and on histological exam * inadequate response or loss of response to corticosteroids, immunomodulators, and/or biologic therapy * crohn's disease activity index (cdai) score ≥ 220 and ≤ 450 * average daily stool frequency ≥ 4 points and/or an abdominal pain of ≥ 2 points * simple endoscopic score for crohn's disease (ses-cd) score of ≥ 6 (or ses-cd ≥ 4 in participants with isolated ileal disease) exclusion criteria: * diagnosis of ulcerative colitis, indeterminate colitis, radiation colitis, or ischemic colitis, or has strictures with prestenotic dilatation requiring procedural intervention * extensive small bowel resection (\>100cm) or known diagnosis of short bowel syndrome, or requires total parenteral nutrition * current stoma, ileal-anal pouch anastomosis, or fistula other protocol-defined inclusion/exclusion criteria apply

Keywords: crohn's disease crohn disease oral ozanimod moderately active severely active rpc01 rpc01-3202
predictors of post-clamping neurologic deficits during carotid endarterectomy with regional anesthesia

Conditions: Carotid Endarterectomy

Summary: patients undergoing carotid endarterectomy may suffer from neurologic deficits (nd) during the carotid cross-clamping due to cerebral hypoperfusion. an associated risk of postoperative stroke incidence is also well established. the aim of this study is to evaluate the predictive factors associated with nd during cea performed with ra. the perioperative implications of the nd were also evaluated.

patients undergoing carotid endarterectomy may suffer from neurologic deficits (nd) during the carotid cross-clamping due to cerebral hypoperfusion. an associated risk of postoperative stroke incidence is also well established. the aim of this study is to evaluate the predictive factors associated with nd during cea performed with ra. the perioperative implications of the nd were also evaluated. all consecutive patients from a tertiary referral center who underwent cea for carotid artery stenosis (cs) and consecutive patients who presented alterations in the neurologic examination after ica clamping during cea are selected. the control patients, submitted to the same procedure but with no neurologic alterations, are consecutively selected.

Eligibility criteria:
inclusion criteria: * carotid endarterectomy under regional anesthesia * postclamping carotid deficit exclusion criteria: * carotid stenting

Keywords: carotid stenosis regional anesthesia
prediction of acute coronary syndrome in acute ischemic stroke

Conditions: Stroke, Ischemic; Acute Coronary Syndrome

Summary: the primary goal of the praise study is to develop a diagnostic algorithm that allows the prediction of acute coronary syndrome in stroke patients with elevated levels of cardiac troponin.

elevation of cardiac troponin can be found in about 30% of patients with acute ischemic stroke (depending on the assay used). elevated troponin indicates increased mortality in stroke patients. there is currently little evidence regarding the ideal care of these patients. the investigators know from previous studies that approximately 25% of acute stroke patients with elevated levels of cardiac troponin have culprit lesions on coronary angiogram. the primary goal of the praise study is to develop a diagnostic algorithm that allows the prediction of acute coronary syndrome in stroke patients. to achieve this, clinical symptoms, troponin levels as well as findings on ekg, echocardiography and coronary angiography will be systematically evaluated. the praise study is a multicenter study with more than 20 sites in germany. joint funding will be provided by dzhk (german center of cardiovascular research) und dzne (german center of neurodegenerative diseases). acute ischaemic stroke patients with elevated troponin are eligible for participation in the study. the primary endpoint is the diagnosis of acute coronary syndrome as established by an independent endpoint committee.

Eligibility criteria:
inclusion criteria: * diagnosis of ischemic stroke based on clinical and imaging information (ct or mri) * diagnosis of transient ischemic attack if the initial focal neurological deficit has been examined by a neurologist and if the abcd2-score is ≥ 4 * elevation of high-sensitive cardiac troponins according to the rule-in/rule-out algorithm of the 2015 esc guidelines for nste-acs, i.e. highly abnormal troponin at 0 hours (\> 52ng/l if hs-ctnt, elecsys-assay, or \> 52ng/l, if hs-ctni; architect-assay, or \> 107 ng/l, if hs-ctni. dimension vista assay) or dynamic change \> 20% of the initial value at re-test after 3 hours with at least one value above the 99th percentile of a healthy reference population * ability to give informed consent * onset of symptoms \< 72 hours prior to hospital admission exclusion criteria: * renal insufficiency (gfr \< 30 ml/min/m²) * contraindications for coronary angiography (e.g. manifest hyperthyroidism, allergy to contrast agent) * lesion size \> 100 ml (either on diffusion weighted imaging on cmri or on ct if ct is performed \> 24 hours after onset) or aspects score \< 7 (on ct if ct is performed \< 24 hours after onset) * premorbid degree of dependence (mrs \> 3) * pregnancy or breast-feeding * limited life expectancy \< 1 year * consent to participate in the study given \> 72 hours after hospital admission

Keywords: stroke troponin acute coronary syndrome culprit lesion
chemo alone or in combination with radiation in unresectable cholangiocarcinoma

Conditions: Cholangiocarcinoma

Summary: the study evaluates impact of high dose radiation on overall survival in patients with unresectable nonmetastatic cholangiocarcinoma. the study randomizes patient between systemic chemotherapy alone and systemic chemotherapy and high dose radiation

currently the standard of care of unresectable non-metastatic cholangiocarcinoma is chemotherapy which has a median survival of 11.7 months (abc-02 study). while this study included almost 60% of patients with cholangiocarcinomas (intrahepatic, extra hepatic and hilar), almost 73-76% of patients in each arm had metastases to begin with. and while the overall survival of the entire cohort was significantly improved by gemcitabine plus cisplatin compared to cisplatin alone, the hazard ratios for intrahepatic {0.57 (0.34-0.94)}, extra hepatic {0.73 (0.43-1.23)} and hilar cholangiocarcinomas {0.59 (0.32-1.09)} were all insignificant. even though concurrent chemoradiation+/= brachytherapy has been used for management of cholangiocarcinomas for more than 3 decades the lack of level i evidence prevents from it being recommended as the first line management across multidisciplinary clinics. while either modality alone rarely yields survival of more than 12 months, recent reports of improved median survival with combination of high dose radiation and systemic chemotherapy necessitates investigation into role of combination of high dose (chemo) radiation and systemic chemotherapy. all patients with diagnosis of nonmetastatic unresectable cholangiocarcinoma who fulfill the study eligibility criteria will be evaluated for study participation. patients will undergo upfront randomization into one of the study arms (systemic chemotherapy alone vs systemic chemotherapy+ high dose radiation) the study stratification criteria will be done according the primary site i.e. intrahepatic vs extrahepatic.

Eligibility criteria:
inclusion criteria: * age \>18 years * performance status 0-2 * tissue diagnosis of adenocarcinoma of the biliary tract. wherever tissue diagnosis is not feasible in spite of repeated attempts a multidisciplinary consensus on clinicoradiological diagnosis of cholangiocarcinoma (ca 19-9= 100mg/ml with a radiological evidence of malignant stricture) should be made and patients consent should be available for treatment without tissue diagnosis. * unresectable disease as determined by hepatobiliary surgical team. * no evidence of peritoneal or distant metastasis. * no radiological evidence of paraaortic nodal disease. * child a or child b (score 7) * ability to tolerate radical treatment. exclusion criteria: * multicentric intrahepatic cholangiocarcinoma (however adjacent satellite lesions are permitted) * inability to deliver safe radiation due to high tumor/ liver ratio. * active cholangitis. * expected survival\<6 months. * unresolved biliary tract obstruction. * inability in deliver systemic chemotherapy (persistent bilirubin\>3)
effect of music therapy on infants with neonatal abstinence syndrome

Conditions: NAS

Summary: this study examines the effects of 6 different music therapy interventions on outcomes for neonates diagnosed with neonatal abstinence syndrome.

the purpose of this exploratory pilot study is to learn what, if any, effects live music therapy interventions have on the pacification, stabilization, and development of infants diagnosed with neonatal abstinence syndrome (nas). neonatal abstinence syndrome is a group of problems that occur in a newborn who has been exposed to illegal or prescription opiates while in the mother's womb. participants will receive 6 music therapy sessions over a 14-day period based on a randomized treatment schedule of 6 different interventions.

Eligibility criteria:
inclusion criteria: infants who meet the following inclusion criteria will be eligible to participate in the study irrespective of race, religion, ethnicity, or gender: * admitted to the nicu immediately postpartum * gestational age 28 weeks or older * no identified hearing disorder * do not have a diagnosed developmental disability (i.e. down syndrome) * do not have fetal alcohol syndrome * medically cleared to participate in the study by nurse or neonatologist * parent or legal guardian able/willing to give consent \& complete the pbq (postpartum bonding questionnaire) exclusion criteria: * admitted to the nicu at any time other than immediately postpartum * gestational age \<28 weeks old * has an identified hearing disorder * has diagnosed developmental disability (i.e. down syndrome) * has fetal alcohol syndrome * is not medically cleared to participate in the study by the nurse or neonatologist * parent or legal guardian unable/unwilling to give consent

Keywords: neonatal abstinence syndrome music therapy attachment music medicine multi-modal stimulation